ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 109 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,198,978 | -22.6% | 81,012 | 0.0% | 0.00% | – |
| Q3 2022 | $1,548,139 | +18.9% | 81,012 | +32.6% | 0.00% | – |
| Q2 2022 | $1,302,382 | +10.6% | 61,116 | 0.0% | 0.00% | – |
| Q1 2022 | $1,177,094 | -78.6% | 61,116 | -77.0% | 0.00% | -100.0% |
| Q4 2021 | $5,504,000 | +277.0% | 265,393 | +334.2% | 0.00% | – |
| Q3 2021 | $1,460,000 | -12.5% | 61,116 | 0.0% | 0.00% | – |
| Q2 2021 | $1,668,000 | -5.7% | 61,116 | 0.0% | 0.00% | – |
| Q1 2021 | $1,768,000 | +197.6% | 61,116 | +189.4% | 0.00% | – |
| Q4 2020 | $594,000 | -4.0% | 21,116 | 0.0% | 0.00% | – |
| Q3 2020 | $619,000 | – | 21,116 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $296,569,000 | 22.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $111,937,000 | 7.03% |
| Pivotal bioVenture Partners Investment Advisor LLC | 671,716 | $18,895,000 | 6.23% |
| Omega Fund Management, LLC | 640,199 | $18,009,000 | 2.70% |
| Orbimed Advisors | 6,073,850 | $170,857,000 | 1.50% |
| Vivo Capital, LLC | 867,170 | $24,393,000 | 1.09% |
| Octagon Capital Advisors LP | 100,000 | $2,813,000 | 0.98% |
| Altium Capital Management LP | 62,962 | $1,771,000 | 0.66% |
| RA Capital Management | 1,165,184 | $32,777,000 | 0.46% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 8,505 | $239,000 | 0.14% |